The QualityStocks Daily Monday, October 10th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(APDN) $2.1200 +70.97%

MarketClub Analysis(IMUX) $6.2000 +56.57%

Tiny Gems(TMNA) $2.1400 +22.29%

The QualityStocks Daily Stock List

UEX Corporation (UEXCF)

We reported earlier on UEX Corporation (UEXCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

UEX Corporation is a junior exploration company with a varied portfolio of projects in Saskatchewan’s Athabasca Basin. Since its establishment, the Company has made major advancements in the discovery and development of existing and new uranium deposits in the Athabasca Basin. UEX is based in Saskatoon, Saskatchewan. The Company also has a satellite office in Vancouver, British Columbia.

UEX is involved in 19 uranium projects, including eight that are 100 percent owned and operated by UEX, one joint venture with Orano Canada, Inc. (Orano) and ALX Uranium Corp. (ALX) that is 50.1 percent owned by UEX and is under option to and operated by ALX, and also eight joint ventures with Orano, one joint venture with Orano and JCU (Canada) Exploration Company Limited that are operated by Orano, and one project (Christie Lake), that is 60 percent owned by UEX with JCU (Canada) Exploration Company Limited which is operated by UEX.

UEX’s underpinning is considerable existing uranium resources. Additionally, the Company is exploring the West Bear Cobalt-Nickel Prospect via its 100 percent owned subsidiary CoEx Metals Corporation. The West Bear Project was earlier part of UEX’s Hidden Bay Project. It contains the West Bear Cobalt-Nickel Prospect and the West Bear Uranium Deposit.

UEX is also increasing its resources at Christie Lake. The new Orora Discovery tested the Company’s first identified new target on this project. Overall, UEX has a large inventory of historical mineralized holes that can undergo follow up to make new discoveries. Fundamentally, UEX’s emphasis is on growing Christie Lake Uranium and enhancing Shareholder value through Cobalt.

UEX Corporation (UEXCF), closed Monday's trading session at $0.3773, even for the day. The average volume for the last 3 months is 79.971M and the stock's 52-week low/high is $0.1832/$0.4495.

Applied DNA Sciences (APDN)

Greenbackers, MarketClub Analysis, OTCPicks, QualityStocks, Free Hot Penny Stocks, StockMarketWatch, MarketBeat, Penny Stock Pick Alert, IRGnews Alert, Wall Street Resources, BUYINS.NET, The PennyStock Picks, Early Bird, Real Pennies, Standout Stocks, Schaeffer's, SuperNova Elite, Super Nova Stock Picks, StreetInsider, TraderPower, We Pick Penny Stocks, Liquid Tycoon, Stock Analyzer, Penny Stock MoneyTrain, StockEgg, Beacon Equity Research, FeedBlitz, Super Hot Penny Stocks, OTCReporter, HotOTC, MicroStockProfit, CoolPennyStocks, Proactivecrg, Penny Stock Finder, OTCtipReporter, Wall Street Grand, PennyStockProphet, PennyStockScholar, PennyTrader Publisher, Trades Of The Day, Penny Stock Solutions, Top Stock Picks, INO Market Report, Lebed.biz, Investor Ideas, Penny Stock Chaser, Penny Pick Finders, Penny Performers, BullRally, HotPennyStocksNow, INO.com Market Report, Dubai Penny Stocks, Marketbeat.com, Micro Cap Pulse, InvestorPlace, Otcstockexchange, Stock Rich, TradersPro, The Penny Play, Stockpalooza, StockOnion, StockHideout, Penny Stock Pick Report, SmallCapVoice, Profitable Trader Authority, PennyStockVille, PennyStocks24, PennyStockCrowd, 24-7 Stock Alert, PennyInvest, Penny stock-pick, Buzz Stocks, StockRich, StockRun, Streetwise Reports, Penny Stock Explosion, ThePUMPTracker, DrStockPick, Daily Trade Alert, HEROSTOCKS and Top Stock Tips reported earlier on Applied DNA Sciences (APDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied DNA Sciences Inc. (NASDAQ: APDN) (FRA: UDJP) is focused on developing and marketing technology solutions which are DNA-based that can be used in the drug manufacturing and developing markets, as well as for anti-theft, anti-counterfeiting and supply chain security applications.

The firm has its headquarters in Stony Brook, New York and was incorporated in 1983. Prior to its name change in 2002, the firm was known as Datalink Systems Inc. It operates as part of the technology sector, under the technology hardware and semiconductors industry. The firm serves consumers in Asia, Europe and the U.S.

The company is focused on offering DNA-based authentication and security solutions and services which protect intellectual property, supply chains, brands, products and assets of consumers, governments and companies from diversion, fraud, counterfeiting and theft.

The enterprise’s product authentication and security solutions include its molecular tags under the SigNature brand, which offer forensic protection and power for different applications. They can be used to strengthen brand protection efforts. This is in addition to tracking and convicting criminals. It also produces the CertainT supply chain platform which offers proof of product claims for products, items or materials; and its SigNify portable DNA readers and consumable reagent test kits, which offer real-time molecular tags authentication.

The firm recently entered into an agreement with Flora Growth to deploy its CertainT platform as part of the latter company’s product validation and authentication platform for government regulators, distributors and consumers. The move will not only bring in additional revenue into the firm but also encourage more investments into the firm.

Applied DNA Sciences (APDN), closed Monday's trading session at $2.12, up 70.9677%, on 80,920,933 volume. The average volume for the last 3 months is 263,374 and the stock's 52-week low/high is $0.6243/$7.35.

Satsuma Pharmaceuticals (STSA)

StreetInsider, MarketBeat, MicrocapVoice, QualityStocks, CoolPennyStocks, Greenbackers, HotOTC, Stock Rich, The Street, Momentum Traders, BullRally, Penny Invest, SmallCapVoice, Stock Stars, StockEgg, Stockpalooza, OTCtipReporter, SmarTrend Newsletters, Stock Fortune Teller, Live2TradeWizely, Daily Trade Alert, StocksAlarm and Schaeffer's reported earlier on Satsuma Pharmaceuticals (STSA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) (FRA: TLV) is a biopharmaceutical firm that is focused on the development of a new therapeutic product for the treatment of acute migraines and other debilitating conditions.

The firm has its headquarters in San Francisco, California and was incorporated in 2016, on June 21st by John Kolins. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States, with a focus on the state of California.

The company is focused on combining great science, cutting-edge technology and proven drug therapies to develop improved therapeutic products that address the various unmet clinical needs of migraine sufferers. The company’s team has extensive experience in the successful development of pharmaceutical products, with special expertise in the area of drug-device combination products delivered through inhalation.

The enterprise’s product pipeline comprises of a proprietary dry-powder DHE (dihydroergotaminemesylate) formulation, dubbed STS101. This formulation is currently in phase 3 clinical trials, being evaluated for its effective use as a differentiated therapeutic option for treating acute migraines. STS101 can be administered without supervision, with a single-use, pre-filled, nasal delivery device. In addition to this, the enterprise has collectively contributed to developing, manufacturing and commercializing over fifty approved drug products.

The company is focused on advancing the development of its STS101 formulation, with its CEO noting that the success of the formulation will favorably position the company in the growing dynamic migraine therapeutics market, which will be good for both its revenues and investments.

Satsuma Pharmaceuticals (STSA), closed Monday's trading session at $6.16, up 14.9254%, on 263,374 volume. The average volume for the last 3 months is 251,040 and the stock's 52-week low/high is $2.51/$8.08.

Cadiz Inc. (CDZI)

MarketBeat, InvestorGuide, MarketClub Analysis, QualityStocks, BUYINS.NET, MissionIR, SmallCap Network, StockMarketWatch, Tiny Gems, SmallCapInvestor.com, StockOodles, StreetInsider, The Street, Investor Update, Investing Futures, Daily Trade Alert and Schaeffer's reported earlier on Cadiz Inc. (CDZI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cadiz Inc. (NASDAQ: CDZI) (LON: 0HS4) (FRA: 2ZC) is a natural resources development firm that is involved in the acquisition, development and management of land with water resources for different uses.

The firm has its headquarters in Los Angeles, California and was incorporated in 1983 by Keith Brackpool. It serves consumers in the United States.

The company is committed to delivering opportunities to increase water access in California. Its main business involves acquiring and developing land with water resources for different uses, including agriculture, groundwater storage and groundwater supply. The company’s projects include the Cadiz Valley Water Recovery, Storage and Conservation.

The enterprise’s primary focus in the development of a water project dubbed the Water Project, which is located in its Cadiz Valley property. The project delivers new water to communities in California. Its properties represent private lands with vested water rights situated in parts of the San Bernardino County. The enterprise also owns roughly 9,000 acres of land in Piute Valley, 2,000 acres of land in the Danby Dry Lake region, nearly 35,000 acres of land in the Cadiz Valley and about 45,000 acres in 3 areas in the Mojave Desert region in Southern California. It is also involved in the fall and spring plantings of grains and vegetables as well as growing lemons.

The firm recently reported a new Schedule 13D by Heerema International Group Services. This move offers support to the company’s strategy to introduce new water storage, supply and conveyance assets which meet the needs of those with water supply shortages. This will positively influence the firm’s revenues as well as its growth.

Cadiz Inc. (CDZI), closed Monday's trading session at $1.88, up 11.9048%, on 251,040 volume. The average volume for the last 3 months is 58,270 and the stock's 52-week low/high is $1.65/$7.615.

Fathom Digital Manufacturing (FATH)

MarketBeat, Schaeffer's, QualityStocks and MarketClub Analysis reported earlier on Fathom Digital Manufacturing (FATH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fathom Digital Manufacturing Corp. (NYSE: FATH) is a digital manufacturing platform that is engaged in the provision of product development and manufacturing services.

The firm has its headquarters in Hartland, Wisconsin and was incorporated in 2020, on December 7th. Prior to its name change, the firm was known as Altimar Acquisition Corp II. It operates as part of the computer hardware industry, under the technology sector. The firm serves consumers in the United States.

The company, which is also known as Kemeera, is at the forefront of the Industry 4.0 digital manufacturing revolution. With decades of experience and over 25 manufacturing processes and a national footprint made up of twelve facilities which make up roughly 450,000 ft2 of manufacturing capacity, the company seamlessly blends in-house capabilities across additive technologies to deliver hybridized solutions designed to meet the low-to-mid-volume manufacturing needs of some of the most innovative and largest firms globally.

The enterprise offers plastic and metal additive manufacturing, injection molding and tooling, computer numerical control machining, urethane casting, design engineering, sheet metal fabrication and chemical etching. It serves clients in a range of sectors, including Internet of Things (IoT), automotive, medical, aerospace, defense and technology.

The company’s latest financial results show increases in its revenues and total orders, with its CEO noting that they remained focused on investing in new technologies and expanding their offerings. This will encourage more investments into the company and generate significant value for its shareholders.

Fathom Digital Manufacturing (FATH), closed Monday's trading session at $1.87, off by 5.0761%, on 58,596 volume. The average volume for the last 3 months is 557,092 and the stock's 52-week low/high is $1.80/$11.50.

Harsco Corp (HSC)

MarketBeat, SmarTrend Newsletters, Zacks, Market Intelligence Center Alert, Schaeffer's, DrStockPick, PennyOmega, CRWEFinance, CRWEPicks, CRWEWallStreet, BestOtc, MarketClub Analysis, PennyToBuck, StreetInsider, INO.com Market Report, StreetAuthority Daily, The Street, StockHotTips, StockMarketWatch, Daily Trade Alert, Dividend Opportunities, BUYINS.NET, Wealth Daily, TradingAuthority Daily, Trades Of The Day, Daily Markets, The Trading Report, Marketbeat.com, FNNO Newsletters, Market FN, Market Intelligence Center, The Stock Enthusiast, The Best Newsletters, QualityStocks and Energy and Capital reported earlier on Harsco Corp (HSC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Harsco Corp. (NYSE: HSC) (FRA: is an industrial services and engineered products firm that is engaged in the provision of environmental solutions for industrial and specialty waste streams.

The firm has its headquarters in Camp Hill, Pennsylvania and was incorporated in 1853. It operates as part of the waste management industry, under the industrials sector. The firm serves consumers across the globe.

The company operates through the Harsco Rail, Harsco Clean Earth and Harsco Environmental. The rail segment provides equipment, after-market parts and services for the repair, maintenance and construction of railway tracks; while the clean earth segment offers processing and beneficial reuse solutions for hazardous wastes, contaminated materials and dredged volumes. This segment also provides waste transportation, processing and services provision with a portfolio of disposal solutions for customers primarily across the industrial, retail and healthcare markets. On the other hand, the environmental segment offers environmental services and material processing to the global steel and metals industries. This segment partners with its global customer base to deliver production-critical on-site operational support and resource recovery services, through management of its customers’ primary waste or byproduct streams. The company's other businesses include providing process equipment, industrial grating and slag abrasives.

The enterprise recently entered into a million dollar agreement with a Saudi Railway Company. This move will allow it to support immediate consumer needs and open it up to new growth opportunities, which will in turn help create value for its shareholders.

Harsco Corp (HSC), closed Monday's trading session at $4.44, up 0.680272%, on 562,452 volume. The average volume for the last 3 months is 3,654 and the stock's 52-week low/high is $3.73/$18.28.

Bragg Gaming (BRAG)

RedChip, QualityStocks, MarketBeat and FreeRealTime reported earlier on Bragg Gaming (BRAG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bragg Gaming Group Inc. (NASDAQ: BRAG) (TSE: BRAG) (FRA: SL4) is global B2B gaming technology platform provider that is engaged in the provision of content and technology to the global gaming industry.

The firm has its headquarters in Toronto, Canada and was incorporated in 2004, on March 17th. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers around the globe, with a focus on Latin America, North America and Europe.

The company has one reportable operating segment; B2B Online Gaming, and operates through the Europe, United Kingdom and North American geographical segments. It mainly operates through its Oryx Gaming International LLC subsidiary.

The enterprise provides comprehensive and bespoke clients solutions delivered with speedy integration completion times through its leading-edge proprietary platform. They include an innovative business-to-business gaming technology platform and casino content aggregator known as Oryx Gaming; and a sports media outlet known as GiveMeSport. The enterprise also offers a range of games, including table, slot, video bingo, card, scratch card, and live dealer games, as well as virtual sports. This is in addition to providing third-party online casino content developed to address the preferences of Canadian and American players. Further, it holds content distribution rights through partnerships with selected third-party studios.

The company recently entered into an expansive iGaming content development partnership with Bally’s Interactive. This move will help extend its reach globally while also generating additional revenues and value for stakeholders of both companies.

Bragg Gaming (BRAG), closed Monday's trading session at $4.22, up 5.7644%, on 3,674 volume. The average volume for the last 3 months is 16,916 and the stock's 52-week low/high is $2.30/$10.89.

Mistras Group (MG)

SmarTrend Newsletters, Super Stock Picker, StreetInsider, MarketBeat, Zacks, DrStockPick, Barchart, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, Marketbeat.com, PennyOmega, PennyToBuck, StockHotTips, AllPennyStocks, INO.com Market Report, Stockhouse, Money Morning, InvestorPlace, BUYINS.NET, Street Insider, The Street, Daily Market Beat and QualityStocks reported earlier on Mistras Group (MG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mistras Group Inc. (NYSE: MG) is a company engaged in the provision of technology-enabled asset protection solutions.

The firm has its headquarters in Princeton Junction, New Jersey and was incorporated in 1978 by Sotirios J. Vahaviolos. It operates as part of the security and protection services industry, under the industrials sector. The firm serves consumers around the globe.

The company operates through the Services, Products and Systems, International Offers segments. The services segment offers asset protection solutions primarily in North America, comprising primarily of non-destructive testing, inspection, mechanical and engineering services. The products and systems segment designs, manufactures, sells, installs and services the firm's asset protection products and systems, including equipment and instrumentation, mainly in the U.S. On the other hand, the international offers segment provides services, products, and systems to markets within the Middle East, Europe, Africa and Asia except South Korea and China, which are served by the Products and Systems segment.

The enterprise provides predictive maintenance assessments of fixed and rotating assets; non-destructive testing services; and inline inspection for pipelines. It also offers maintenance and light mechanical services, such as insulation installation and removal, corrosion removal, electrical, mitigation and prevention, heat tracing, industrial cleaning, pipefitting, and welding. The enterprise serves various industries, including the oil and gas, fossil and nuclear power, commercial aerospace and defense, transportation and process, and renewable energy.

The firm recently announced its latest financial results, which show increases in its revenues. It remains focused on expanding its service offerings, which will bring in additional revenues into the firm.

Mistras Group (MG), closed Monday's trading session at $4.75, off by 0.835073%, on 16,924 volume. The average volume for the last 3 months is 428,057 and the stock's 52-week low/high is $4.39/$11.29.

LG Display (LPL)

InvestorPlace, MarketBeat, Zacks, Kiplinger Today, StockMarketWatch, The Street, Daily Trade Alert, Marketbeat.com, TheStockAdvisor, Louis Navellier, Trades Of The Day, Market Intelligence Center Alert, The Motley Fool, BUYINS.NET, MarketClub Analysis, Uncommon Wisdom, StreetInsider, SmarTrend Newsletters, ChartAdvisor, Daily Profit, Wyatt Investment Research, Forbes, Wealth Daily, Schaeffer's, Trade of the Week, TopStockAnalysts, Top Pros' Top Picks, The Online Investor, Money and Markets, QualityStocks and Wall Street Daily reported earlier on LG Display (LPL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LG Display Co. Ltd (NYSE: LPL) (FRA: LGA) (KRX: 034220) (VIE: LGA) is a company focused on designing, manufacturing and selling organic light emitting diode (OLED) and thin-film transistor liquid crystal display (TFT-LCD) technology-based display panels.

The firm has its headquarters in Seoul, South Korea and was incorporated in 1985, on February 28th. Prior to its name change in March 2008, the firm was known as LG Philips LCD Co. Ltd. It operates as part of the consumer electronics industry, under the technology sector. The firm serves consumers around the globe.

The company is focused on growing sustainably as it continues to provide greater value to its consumers. It carries out direct sales through overseas subsidiaries in various nations, which include Singapore, the United States, Japan, Germany, China and Taiwan. These subsidiaries provide technical support to clients in addition to conducting sales activities. The company generates the majority of its revenue from overseas markets, deriving the rest from South Korea.

The enterprise’s OLED and TFT-LCD technology-based display panels are primarily used in televisions, desktop monitors, notebook computers, mobile devices, tablet computers and automotive displays. It also offers display panels for industrial and other applications, including portable navigation devices, entertainment systems and medical diagnostic equipment.

The firm is currently focused on strengthening its position in the premium market and accelerating new businesses in the display sector. This will not only bring in additional revenues and investments into the firm but also extend its consumer reach, which will open the firm up to new growth opportunities.

LG Display (LPL), closed Monday's trading session at $4.63, off by 1.9068%, on 428,144 volume. The average volume for the last 3 months is 13.312M and the stock's 52-week low/high is $4.08/$10.78.

Nikola Corporation (NKLA)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, MarketBeat, The Street, QualityStocks, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Zacks, Cabot Wealth, Early Bird, Wealth Insider Alert, CNBC Breaking News, Louis Navellier, MarketTamer, Outsider Club, StockMarketWatch, Investopedia and Daily Profit reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

You have probably heard about the massive recall of the Chevrolet Bolt EV due to a defect that significantly increased the risk of fires. After dozens of Chevy Bolts broke out into flames in 2020, General Motors first recalled the model in November before issuing three more recalls in July 2022.

With all this media talk about electric vehicle fires, you are probably wondering if it would be a good (and safe) idea to purchase an EV, especially if you have little or no experience with one before. Data shows that the 2019 Bolt EV with an LG-manufactured battery is nearly 35 times more likely to catch fire than a similar gas-powered model produced in 2019, after all.

It would be easy for a novice to believe that given the large battery stored along the bottoms of electric cars, they present a much higher risk of fire and are essentially ticking bombs. However, that couldn’t be further from the truth. Despite the Bolt’s much higher risk of fire, the average electric vehicle is much less likely to catch fire compared to a similar gasoline-powered car.

Since electric cars still make up a pretty small percentage of total vehicle sales, researchers from Auto Insurance EZ compared the number of fires for every 100,000 cars sold. The researchers drew data on fire accidents from the National Transportation Safety Board and the Bureau of Transportation Statistics, finding that there were 3,474.5 hybrid fires per 100,000 vehicles, 1,529.9 gasoline car fires, and only 25.1 electric vehicle fires per 100,000.

Media coverage of electric vehicle fires has made it seem like EV fires are much more common. EVs are a new and disruptive technology, meaning they attract plenty of media attention. The presence of a few fires makes for entertaining reporting, especially at a time when electric vehicles are getting a lot of mainstream attention.

Furthermore, extinguishing electric vehicle fires calls for a ton of effort from emergency personnel due to a chain reaction that causes EV batteries to produce more heat than they can dissipate. EV fires are also harder to extinguish than gas car fires, usually requiring tens of thousands of gallons of water, as the lithium-ion batteries within take much longer than gasoline to burn out.

But as the EV industry evolves and matures, car manufacturers such as Nikola Corporation (NASDAQ: NKLA), product safety advocates and law enforcement will likely come up with safety standards and methods to respond to EV fire issues. In the meantime, drivers should know that the risk of encountering an electric vehicle fire is significantly lower than a conventional vehicle fire.

Nikola Corporation (NKLA), closed Monday's trading session at $3, off by 7.6923%, on 13,312,106 volume. The average volume for the last 3 months is 9.689M and the stock's 52-week low/high is $2.88/$15.56.

Marathon Digital Holdings Inc. (MARA)

NEWSLETTER Field, InvestorPlace, MarketClub Analysis, Schaeffer's, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, StocksEarning, Lebed.biz, The Online Investor, Trades Of The Day, The Street, Daily Trade Alert, TraderPower, Marketbeat.com, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, FeedBlitz, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, InvestorsUnderground, Barchart, DreamTeamNetwork, RedChip, AllPennyStocks, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Decentralized blockchain technology took the world by storm when it was first introduced more than a decade ago. Blockchain and crypto promised to deliver enhanced security and privacy, visibility, traceability, fast transactions and immutability. The crypto market grew increasingly popular over the years and attracted millions of users, especially those from developing countries because they traditionally have limited access to investing.

With a valuation of $1.6 billion in 2021, the cryptocurrency market is expected to be worth $2.2 billion by 2026. As the market has grown and evolved, there have been efforts by lawmakers in regions that allow cryptocurrencies to pass some kind of crypto policies. The European Union parliament recently did just that by approving a nonbinding resolution calling for the passage of tax policies for the blockchain and cryptocurrency market.

These regulations would allow for the use of blockchain to coordinate crypto tax policies and fight tax evasion. Tax experts have long said that cryptos such as Bitcoin and Ethereum can provide a way for people to hide their income from the taxman due to lax reporting requirements. Members of the EU parliament voted in favor of a resolution that urges leaders in the 27 member states to consider creating a “simplified tax treatment” for cryptocurrency users.

Authorities in member states are also encouraged to consider having national tax administrations that leverage blockchain to “facilitate efficient tax collection,” the resolution said. It also called on the European Commission to analyze whether or not to tax the conversion of digital tokens to fiat currency depending on the location of the transaction. Furthermore, the policy asked for an administrative exchange to make the exchange of information on crypto taxes more efficient.

The resolution stated that member states could automate tax collection, reduce instances of corruption, and pinpoint ownership of intangible and tangible assets using blockchain technology. Furthermore, it stated that member states would have to work on figuring out best practices that would make it possible to use technology to boost tax administrations’ analytical capacity.

European Union lawmakers are already taking steps to regulate the cryptocurrency market on the continent. Policymakers introduced the Crypto-Assets Framework back in 2020, which was adopted by the EU in 2021. The bill looks to launch a standardized regulatory framework for cryptos in EU member states and is expected to take effect in 2024. This would make Europe the first continent in the world to pass standard crypto-asset policies.

As more jurisdictions enact policies regulating cryptos and blockchain, industry operators such as Marathon Digital Holdings Inc. (NASDAQ: MARA) are likely to gain even more acceptance among members of the public that were wary of this new and disruptive technology.

Marathon Digital Holdings Inc. (MARA), closed Monday's trading session at $10.76, off by 4.0143%, on 9,727,984 volume. The average volume for the last 3 months is 10,380 and the stock's 52-week low/high is $5.20/$83.45.

Field Trip Health Ltd. (FTHWF)

We reported earlier on Field Trip Health Ltd. (FTHWF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Neuroplasticity is the brain’s ability to change, modify and adapt its structure and function over the course of life as a response to various experiences. This ability is often disrupted in the early stages of depression, with negative stimuli such as stress causing changes in neuroplasticity that play a major role in the development of depression.

Treatments meant to alleviate depression work by acting on neural plasticity to increase the brain’s plasticity and adult neurogenesis. In recent years, the scientific community has increasingly turned its eyes to psychedelic drugs as alternative treatments for mental health conditions, including depression.

Initial studies have found that hallucinogenic drugs such as psilocybin, ketamine, and MDMA can be effective at alleviating the symptoms of mental illnesses, including post traumatic stress disorder and treatment-resistant depression. Studies have found that psychedelic-assisted therapies are especially effective when they are paired with psychotherapy.

One such study found that MDMA or ecstasy has the ability to ‘resensitize’ the brain of adults mice and allow them to adapt to their social environment in a way that is typically reserved for teenage years. Childhood and teenagehood represent ‘critical periods’ where external stimuli can cause long term changes to the brain due to plasticity.

However, neuroplasticity fades as we age, and it becomes harder for the brain to adapt to environmental stimuli like it once could.

Speaking in a recent interview, neuroscientist Gül Dölen who spearheaded the 2019 study, stated that MDMA was able to restart the critical period for social development long after it had closed. Dölen and his team studied more than 1,000 mice at 15 different ages, discovering that plasticity was triggered by oxytocin in a region of the brain called the nucleus accumbens in young animals.

Since oxytocin cannot cross the blood-brain barrier, meaning researchers couldn’t use it to directly trigger plasticity, they had to find another way to induce the mechanism. Unlike modern researchers who are more concerned with the more immediate effects of taking MDMA, Dölen wanted to see how the drug would affect animal subjects over the long term. After observing the mice 48 hours after they were dosed with MDMA, the researchers found that the mice had renewed social reward learning even though this critical learning period should have been closed permanently.

Test mice were able to quickly associate one type of bedding with a more social setting and begin spending more time in that bedding. In comparison, adult mice don’t form such connections rapidly and spend the same amount of time in different bedding regardless of the social situation of each.

Researchers could use MDMA’s groundbreaking ability to reopen the critical period to expand the kinds of mental health illnesses psychedelics can treat.

Other teams, such as those at Field Trip Health Ltd. (OTC: FTHWF) (TSX.V: FTHW), are also studying a variety of active psychedelic compounds with a view to formulating remedies that will revolutionize the way people with mental health conditions have been treated for decades.

Field Trip Health Ltd. (FTHWF), closed Monday's trading session at $0.146, up 4.2857%, on 10,380 volume. The average volume for the last 3 months is 104,582 and the stock's 52-week low/high is $0.0177/$0.50.

The QualityStocks Company Corner

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture partner Zylö Therapeutics in developing a topical sustained released ketamine utilizing Z-pod(TM) technology,” said Eric Weisblum, CEO of Silo Pharma. “Preclinical studies have already shown that our joint developed delivery method and formulation can hold and distribute ketamine in a time-released manner. SP-26 reported positive results in reducing neuropathic nerve pain. This safety evaluation study will uncover maximum tolerated dosing data that will inform our future trials.” To view the full press release, visit https://ibn.fm/Os7FW

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Monday's trading session at $5.75, up 1.0545%, on 104,728 volume. The average volume for the last 3 months is 628,581 and the stock's 52-week low/high is $4.46/$12.445.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , and The Chopra Foundation (“Foundation”), a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, join everyone in recognizing World Mental Health Day. The two organizations continue to work toward the research and education of psychedelic-based therapies and their role in enhancing well-being and consciousness. According to the World Health Organization (“WHO”), over 900 million people are affected by mental illness around the world. The pandemic has increased the number of individuals that are affected by different forms of mental illness. In 2021 the WHO released data that over 280 million people were affected by depression.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.64, up 6.5069%, on 631,143 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $12.445/$.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety

In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the players

According to a report published by Vox, there are approximately 0.41 concussions per NFL game in American football, with 9.3% of concussions involving the loss of consciousness and 2.4% resulting in hospitalizations

With such cases, there is a need to revise the NFL’s concussion protocol and push for a treatment option that is effective in the treatment of this condition

Odyssey is at the forefront of a possible pharmaceutical treatment option, as it advances its clinical trials, to potentially receive FDA approval

Odyssey Health (OTC: ODYY) is looking to push its PRV-002 novel compound for the treatment of concussions given the National Football League (“NFL”) and National Football League Players Association’s (“NFLPA”) joint announcement on changes to the league’s concussion protocol ( https://ibn.fm/LOjTi ). Concussions are a type of brain injury that occurs when the head is struck hard enough that the brain smacks against the skull and is damaged. Such injuries can also happen when the body is shaken violently enough to cause the brain to move around in the skull, such as during whiplash. As with most head injuries, concussions can have major consequences if they are severe or not treated early enough. Over the long term, some patients may develop a condition called post-concussion syndrome , which is characterized by dizziness, headaches and problems with memory and concentration. Aside from car accidents, concussions are overwhelmingly common in sports such as football and boxing, which involve a degree of physicality. According to neuroscientist professor Alan Pearce, the risk of concussive injuries in such sports has been increased by the myth that helmets are capable of protecting the wearer from these injuries.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Monday's trading session at $0.32, up 11.8838%, on 120,389 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.11/$0.64.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run. The event is taking place on Saturday, Nov. 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me. Supporting these patients, their journey and the challenges they currently endure is not just a priority for us, it is why we do what we do,” Climaco said. “Across the globe there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families and to raise much needed funds for research.” To view the full press release, visit https://ibn.fm/SFOTM

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.1986, up 3.0618%, on 89,175 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1662/$1.55.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • REZYFi is a specialized financing company in the U.S., originating, structuring, and investing in first mortgage loans and alternative structured financings secured by commercial real estate properties
  • Target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing
  • Currently licensed in 36 states, with plans for expansion into all states, REZYFi is leveraging its experience, a network of independent brokers, and proprietary technology, to enhance its offering within target markets
  • REZYFi operates through two wholly-owned subsidiaries – REZYFi Lending and ResMac, Inc. – offering financial services and direct lender/originator options across a large network of correspondents

The cannabis industry overall has been experiencing significant growth, with double-digit rates, and companies are competing to gain a significant market share. Leading players in the cannabis market are undertaking inorganic growth strategies, including expansions, investments, and acquisitions, to increase their profits and share of the market. The worldwide market is expected to be valued at $27.7 billion in 2022 and projected to reach $82.3 billion by 2027, recording a CAGR of 24.3%, driven by the increased legalization of cannabis for recreational and medical purposes use in countries ( https://ibn.fm/8xmWf ). Mortgage lender company REZYFi , servicing the needs of both traditional and non-traditional consumers and businesses, is positioned to be one of the first cannabis mortgage bankers in the United States – an industry where many traditional lenders are reticent to serve the state-licensed cannabis industry.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

CO2 concentrations in the atmosphere are at the highest of the modern record era

EverGen develops and operates renewable natural gas projects that significantly reduce pollutants like CO2 and methane

With major customers and partners, EverGen has expanded from a single facility in British Columbia to a series of projects across Canada

Natural gas prices are soaring around the world, partly contributing to the inflation in Europe that has risen to a record 10% in September. At the same time, citizens in New Jersey gripe over state regulators approving natural gas rate hikes that went into effect Saturday ahead of the cold weather season. While prices rise and all eyes are on natural gas, the climate change debate rages on. Throwing fuel into the fire, a special supplement to the bulletin of the American Meteorological Society that was released in August, paints an eye-popping picture of the level of carbon dioxide (“CO2”) in the atmosphere. Decarbonization isn’t easy, but thankfully, there are companies like EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) that are rising to the challenge to provide RNG solutions for utilities who are increasingly looking to reduce the world’s dependence on fossil fuels and slash pollution.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Monday's trading session at $1.46, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $1.46/$4.21.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

Reklaim appears poised to capitalize on new market opportunities for companies with a competitive edge in compliant data; it seeks to position itself as the go-to privacy-compliant data partner

Shifting data-protection regulations and stricter privacy policies of Big Tech companies like Apple and Google require brands to replace their existing data suppliers with those compliant with new privacy standards

Reklaim’s platform allows consumers to claim control of their personal data while brands can buy and sell consumer-consented privacy-compliant data

As the era of online tracking and monetizing consumer data without explicit consent is coming to an end, companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) that provide consumer data compliant with government regulations are set to benefit in this rapidly evolving environment. Driven by the transformation of consumer privacy regulations and how Big Tech has adapted to this changing consumer sentiment and legislation, Reklaim appears poised to position itself as the go-to solution for businesses under swelling pressure to find a partner to solve this compliance gap.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online (www.ReklaimYours.com) and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Monday's trading session at $0.0461, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0387/$0.3859.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Several developed nations have passed a host of sanctions against Russia in a global bid to stop its misguided war in Ukraine. Months after Russia declared war on Ukraine and breached its borders, dozens of countries placed sanctions on Russian exports, limited the movement of Russian money and cut the country off from critical exports. However, despite efforts by the United States to distance itself from Russian exports , it seems Washington will have a hard time weaning itself off of Russian nuclear fuel. Since Russia is one of the top energy producers in the world, several countries rely on it as a source of energy. Europe, for instance, has been gripped by a historic energy crunch for the past few months after Russia cut natural gas exports to the rest of the EU. Despite efforts by the U.S. government, Russia’s top position in global energy will make it hard for the nation to completely cut itself from the federation. Russia controls around two-fifths of enrichment services worldwide and supplies nearly 25% of the fuel used in 93 operational American nuclear reactors. Weaning itself off energy supplies from Russia will be a challenge as the country is deeply ensconced in the supply chain. Although some U.S. companies have indicated that they would resume local production if they signed long-term supply contracts with nuclear power producers, it would take a while before local production matches supplies from Russia and its allies, even if entities such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are willing to supply all the needed uranium to the domestic facilities focused on processing and enriching it for use at power plants.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $6.15, off by 8.8889%, on 2,599,629 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.69/$11.39.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT) is a cardiac technology company whose initial focus is on providing diagnostic data through its 3D-vector 12-lead electrocardiogram (“ECG”) platform – the first and only to be developed – for heart attack detection anytime, anywhere. Its development portfolio includes HeartBeam AIMI(TM), a software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately and speedily identify a heart attack in acute care settings. Also under development is HeartBeam AIMIGo(TM), the first and only credit card-sized 12-lead output ECG device for remote heart attack detection that combines a smartphone app and cloud-based diagnostic software system. “The company’s proprietary ECG telehealth technology aims to redefine the way high-risk cardiovascular patients are diagnosed in ambulatory and acute care settings… In August 2022, HeartBeam announced that it submitted HeartBeam AIMI software for approval from the U.S. Food and Drug Administration (‘FDA’)… The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023,” a recent article reads. “HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause.” To view the full article, visit https://ibn.fm/HYGu7

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Monday's trading session at $4.65, off by 19.8276%, on 1,106,638 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Cannabis grower and product maker Flora Growth is developing its own approach to riding troubling economic forces, boasting a 604 percent YOY increase in the H1 reporting period this year

Market analysts predict the global cannabis market’s value will rise during the next five years at a CAGR of 24.3 percent to arrive at annual valuation of $82.3 billion

Flora Growth is levying the potential of recent cooperative agreements to increase the reach of its product distribution pipeline, including new exports to Switzerland, the Czech Republic and the United States

Europe is predicted to be the fastest-growing region for cannabis sales during the next few years as a result of Europeans’ recognition of cannabis’ medical benefits and the ongoing advance of legalization

Cannabis cultivator, brand manufacturer and global distributor Flora Growth (NASDAQ: FLGC) is offering a bit of pain relief to economies battered by recent uncertainty over a costly worldwide pandemic, a war in Europe’s breadbasket and the retail supply chain disruptions that have resulted from them.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $0.6295, off by 7.8196%, on 408,162 volume. The average volume for the last 3 months is 408,162 and the stock's 52-week low/high is $0.586/$5.61.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX) , the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, provides a new income opportunity for farmers. The company’s GrowPods, or unique controlled environment farms, offer the ideal environment for farmers to grow crops all year long; as an added advantage, the crops are high nutrient, clean and sustainable. According to the announcement, recent reports have highlighted the challenges that farmers face, including increasing debt, extreme weather conditions, consolidation, degrading and eroding soils, and increased pesticide and chemical use that impact the nutrient value of harvests. One study noted that farmers are among the highest suicide rate profession in the country. ACTX’s GrowPods address this crisis. The hydroponic controlled environment farms can grow an estimated acre of food using about one-third of the water that traditional farming requires. One article reported that controlled environment farms are “100 times more productive than traditional agriculture,” while another noted that controlled environment agriculture is reshaping farming by using advanced horticultural and engineering techniques to optimize crop production, quality and efficiency “Our food system is in peril, and we can no longer keep going on as if everything is fine,” said ACTX CEO Doug Heldoorn in the press release. “It's time for farmers to look to new ways of growing crops that don't depend on soil, and don't require chemicals or pesticides. . . . Our nation's farmers need new tools and techniques to survive. GrowPods offer a pathway forward to a more sustainable future.” To view the full press release, visit https://ibn.fm/J7bua . Hurricane Ian has left structural damage and destruction in its wake, with more than 100 cannabis businesses in Florida being forced to close. Data from the National Hurricane Center and the Florida Office of Medical Marijuana Use show that over one-half of the medical cannabis stores in the state of Florida are located in the direct path of the potential storm surges and excessive rainfall. Some of the medical cannabis retailers operating in the state have been providing updates on closures via social media as well as through their websites. This includes Liberty Health Sciences, which closed 39 of its 51 dispensaries but has since reopened its stores located in West Palm Beach, Stuart, Port St. Lucia and Dania Beach. The enterprise is a unit of Ayr Wellness, which is based in Miami. Trulieve Cannabis, the biggest dispensary operator in the state, also closed 55 of its 120 stores. In addition to this, MÜV also shut down about 30 of its 59 stores last week. Cannabis business operators in other regions are also preparing for the storm. For instance, Brandon Johnson, CEO and founder of TRP, revealed that TRP’s primary concern was employee safety. Other companies, such as Weedgets, have gone the extra mile, ensuring that their employees were safe and that their inventory was moved to elevated locations to avoid any damage. It is in such situations that the usefulness of vertical growing equipment from companies such as Advanced Container Technologies Inc. (OTC: ACTX) may have limited possible damage to commercial indoor cultivation operations.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Monday's trading session at $0.3755, off by 24.9%, on 500 volume. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.

EOR

In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.

FORWARD-LOOKING STATEMENTS

This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Monday's trading session at $0.142, even for the day, on 1,900 volume. The average volume for the last 3 months is 1,900 and the stock's 52-week low/high is $0.049/$0.2714.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.